Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.694728
Title: Novel epigenetic biomarkers for the Barrett's-adenocarcinoma sequence in oesophageal cancer
Author: Dilworth, Mark
Awarding Body: University of Birmingham
Current Institution: University of Birmingham
Date of Award: 2016
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
Introduction Oesophageal adenocarcinoma presents an ever increasing challenge to the NHS, with rising incidence and poor overall survival. There are few robust biomarkers available for this disease – either for detection or stratification. Barrett’s Oesophagus, a precursor to adenocarcinoma, is common. In the non-dysplastic setting, few patients will progress to cancer. There are no current biomarkers to aid in this stratification process. Aims To assess the role of methylation biomarkers in the context of diagnosis of adenocarcinoma and their role in tumour biology. To provide a methylation stratification tool in the identification of high risk non-dysplastic Barrett’s Oesophagus. Methods Genome wide methylation assessment was performed with validation using bisulphite pyrosequencing on carefully selected tissues to reveal novel methylation biomarkers Results Methylation of TRIM15, has been shown to be a robust biomarker in disease identification and has a role in tumour biology. OR3A4, a long none coding RNA, has been identified as a way to reliably risk stratify the non-dysplastic Barrett’s patient and forms the first biomarker of this kind. Conclusions Methylation biomarkers play a key role in disease identification and risk of cancer development. They also appear to play a role in tumour biology.
Supervisor: Not available Sponsor: University Hospital Birmingham Charities ; Upper GI Support Group
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.694728  DOI: Not available
Keywords: RD Surgery
Share: